Multiple sclerosis is a chronic autoimmune disease that attacks the central nervous system. It affects people of all ages, but it is most commonly diagnosed in young adults between the ages of 20 to 40.

This disease can cause a wide range of symptoms such as fatigue, pain, muscle weakness, and problems with balance and coordination.

Oral therapy for multiple sclerosis

Oral therapy has emerged as a new treatment option for patients with multiple sclerosis. These drugs are taken by mouth, and they work by modulating the immune system to reduce inflammation and prevent damage to the nerves.

There are several oral therapies available, including:.

Fingolimod

Fingolimod is an oral medication that has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis.

It works by trapping immune cells in the lymph nodes, preventing them from reaching the central nervous system where they can cause damage. Clinical trials have shown that like other MS therapies, Fingolimod reduces relapse rate and slows the progression of disability.

Teriflunomide

Teriflunomide is also an oral medication that has been approved by the FDA to treat relapsing forms of multiple sclerosis. It blocks the formation of immune cells, reducing the number of attacks on the nervous system.

Clinical trials have shown that Teriflunomide helps to slow the progression of disability in patients with MS.

Dimethyl fumarate

Dimethyl fumarate is an oral medication that has been approved by the FDA to treat relapsing forms of multiple sclerosis. It works by reducing inflammation and protecting the nerves from further damage.

Clinical trials have shown that Dimethyl fumarate reduces the number of relapses and prevents the progression of disability in patients with MS.

Glatiramer acetate

Glatiramer acetate is another type of oral medication that has been approved by the FDA to treat relapsing-remitting multiple sclerosis. It works by altering the immune system to reduce inflammation and prevent further damage to the nerves.

Clinical trials have shown that Glatiramer acetate slows the progression of disability and reduces the number of relapses in patients with MS.

Positive effects of oral therapy on multiple sclerosis patients

Oral therapy has been found to have many positive effects on the overall well-being of multiple sclerosis patients. Some of these benefits include:.

Reduced relapse rates

Studies have shown that oral medications for treating multiple sclerosis can significantly reduce the number of relapses that patients experience.

This can lead to an improved quality of life as well as a reduced need for hospitalization and medical intervention.

Improved physical function

Oral therapy has also been found to improve physical function in multiple sclerosis patients. Patients who take oral medications may experience better mobility, less muscle weakness, and less fatigue than those who do not take medication.

Decreased risk of disability

Studies have also shown that oral medications for multiple sclerosis can decrease the risk of disability in patients. This can help patients to maintain their independence and maintain their quality of life for longer periods of time.

Enhanced psychological well-being

Multiple sclerosis can be a very stressful and emotionally draining disease. Oral therapy has been found to enhance psychological well-being in patients, as it can help alleviate symptoms that contribute to depression and other psychological issues.

Conclusion

Oral therapy has emerged as an effective treatment option for multiple sclerosis patients. These medications have been found to reduce relapse rates, improve physical function, decrease the risk of disability, and enhance psychological well-being.

Patients who are beginning to experience symptoms of MS should consult with their medical professionals to determine if oral therapy is right for them.